Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.
In this week's EuroBiotech Report, an investment vehicle backed by the megarich family that founded Serono plans to merge Stallergenes with Greer to create a transatlantic allergy immunotherapy player that can go toe-to-toe with Circassia and Merck. Cerenis Therapeutics has big plans of its own. And more.
Big Pharma-backed Opsona Therapeutics has looked into its future and seen a possible IPO on the horizon. The Dublin, Ireland-based immunology drug developer made the pronouncement as its lead candidate graduated to the second part of an adaptive Phase II trial.
Cerenis Therapeutics has filed the paperwork for an IPO in Europe as it looks to bounce back from the failure of a Phase II trial of its HDL-like drug.
An investment fund backed by the megarich family that founded Serono has proposed merging Stallergenes and Greer. The fund is well placed to make such a deal happen: It has a 77.3% stake in Stallergenes and owns Greer outright.
The United Kingdom government has made the life science industry a focal point of its turnaround strategy, but data that have dripped out over the past few months show companies are spending less and less on developing and manufacturing drugs in the state.
Former Elan CEO Kelly Martin and other people with links to the Irish drugmaker are aiming to raise up to €325 million ($364 million) in an IPO to bankroll their life science investment fund. The IPO on the Irish Stock Exchange could dwarf last year's listing by Circassia and become one of the biggest floats in European biotech history.
In this week's EuroBiotech Report, Woodford looks set to go all in on south east England's academic hotspots. The U.K. government is set to further bolster the credentials of the region by setting up an international dementia institute within 5 years and lending its support to a dementia R&D investment fund. Prexton Therapeutics grabbed a slice of the CNS funding that is available today, raising €8.7 million ($9.9 million) to take its Parkinson's disease candidate into the clinic. And more.
Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.
Prexton Therapeutics, the first company to emerge from the €30 million ($34 million) biotech-creation program Merck Serono set up amid the shuttering of its Geneva R&D center, has closed a Series A round.